Cytochrome P450 family 1 subfamily A member 1 (CYP1A1) (CYP1A1)

Cytochrome P450 1A1 (CYP1A1) is a critical phase I enzyme primarily involved in the oxidative metabolism of xenobiotics, including polycyclic aromatic hydrocarbons (PAHs) and various environmental pollutants [1.1.1, 1.2.1]. While it also metabolizes endogenous compounds such as estradiol, its most significant biological role is the dual capacity for detoxification and the bioactivation of procarcinogens into highly reactive, DNA-damaging intermediates [1.1.3, 1.3.1]. The expression of CYP1A1 is tightly regulated by the Aryl hydrocarbon receptor (AhR) signaling pathway, which translocates to the nucleus upon ligand binding to induce gene transcription [1.1.1, 1.2.2]. In drug development, CYP1A1 is targeted for chemoprevention using inhibitors that block carcinogen activation and is exploited in oncology for the selective activation of prodrugs within tumors [1.1.2, 1.4.1]. However, the induction of this pathway by environmental toxins or certain pharmaceuticals presents major safety challenges, including an elevated risk of chemical carcinogenesis and potential cardiotoxicity [1.1.1, 1.3.3]. The input name 'CYP1A1 expression pathway' is considered incorrect as it refers to a biological process rather than a single target molecule, though the enzyme CYP1A1 is the primary functional component of this pathway.

Other names

Aryl hydrocarbon hydroxylaseAHHCytochrome P1-450CYP1Cytochrome P450-CCytochrome P450-P1

Drugs targeting the CYP1A1 pathway primarily act through three mechanisms: competitive or non-competitive inhibition of the CYP1A1 enzyme to prevent the bioactivation of procarcinogens; induction of CYP1A1 gene expression via activation of the Aryl hydrocarbon receptor (AhR); and metabolic activation of prodrugs (e.g., duocarmycin derivatives) into cytotoxic agents specifically within tumors that overexpress the enzyme [1.1.1, 1.1.2, 1.1.3].